Glenmark Life Sciences Ltd Share Price (GLS)
₹617.95
Overview of Glenmark Life Sciences Ltd
Key events for Glenmark Life Sciences Ltd
Nirma to Acquire Majority Stake in Glenmark Life Sciences - 22 Sep, 2023
Nirma Ltd has agreed to acquire a 75% stake in Glenmark Life Sciences for ₹5,651.5 crore and will make a mandatory open offer for an additional 17.15% stake at ₹631/share. Meanwhile, Glenmark Pharma is set to sell its majority stake in the life sciences unit for $680 million.
Nirma Acquires Majority Stake in Glenmark Life Sciences - 21 Sep, 2023
Glenmark Pharmaceuticals sells a 75% stake in Glenmark Life Sciences to Nirma Ltd for Rs 5,652 crore. The company will operate independently under new ownership.
Glenmark Life Sciences Included in Nifty 500 Index - 17 Aug, 2023
Glenmark Life Sciences Ltd will be added to the Nifty 500 index, as per a recent announcement.
Glenmark Life Sciences Added to MSCI Global Small Cap Index - 11 Aug, 2023
Glenmark Life Sciences Ltd has been added to the MSCI Global Smallcap Index, effective from August 31.
Nirma Eyes Acquisition of Glenmark Life Sciences - 28 Jul, 2023
Nirma is planning to acquire companies in the healthcare sector and has shortlisted Glenmark Life Sciences for financial bids. The acquisition will help Nirma diversify its portfolio.
Nirma Group Shortlisted for Glenmark Life Sciences Bid - 27 Jul, 2023
Glenmark Life Sciences witnesses remarkable growth, touching a 52-week high of Rs 673.2. Nirma Group is shortlisted to make a financial bid for the company, which may cost up to Rs 6,000 crore.
Glenmark Life Sciences Reports Strong Q1 Results and Successful IPO - 21 Jul, 2023
Glenmark Life Sciences reports a 24% YoY increase in net profit for Q1 2023, while its IPO is subscribed 2.78 times on the second day of bidding, leading to a new 52-week high at Rs. 658.
Nirma and Sekhmet among final bidders for controlling stake in Glenmark Life Sciences - 15 Jul, 2023
Nirma Ltd. and Sekhmet Pharmaventures, backed by PAG, are among the final bidders for a controlling stake in Glenmark Life Sciences valued at about $731 million. The move comes as Glenmark Pharma looks to raise cash and cut debt.
Shortlisted Bidders for Controlling Stake in Glenmark Life Sciences - 14 Jul, 2023
Nirma Ltd. and PAG-backed Sekhmet Pharmaventures are among the shortlisted bidders for a controlling stake in Glenmark Life Sciences Ltd.
Analyst Rating for Glenmark Life Sciences Ltd stock
based on 5 analysts
Based on 5 analysts offering long term price targets for Glenmark Life Sciences Ltd. An average target of ₹708.2
Source: S&P Global Market Intelligence
Glenmark Life Sciences Ltd share Performance
- ₹617.05₹626.9₹617.95
0.15%
Downside
Day's Volatility:1.59%
Upside
1.45%
- ₹370₹675₹617.95
40.12%
Downside
52 Weeks Volatility:49.36%
Upside
9.23%
| Returns % | |
| 1 Month Return | 0.61 % |
| 3 Month Return | 9.26 % |
| 1 Year Return | 63.47 % |
| Market Stats | |
| Previous Close | ₹621.85 |
| Open | ₹623.90 |
| Volume | 1.82L |
| Market Cap | ₹7,619.35Cr |
Glenmark Life Sciences Ltd Company Information
Share Price: ₹617.95 per share as on 29 Sep, 2023 04:01 PM
Market Capitalisation: ₹7,619.35Cr as of today
Listing date: 06 Aug, 2021
Chairperson Name: Glenn Saldanha
| Organisation | Glenmark Life Sciences Ltd |
| Headquarters | |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Fundamentals of Glenmark Life Sciences Ltd
Insights on Glenmark Life Sciences Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTMF Holding Up
Mutual Funds have increased holdings from 0.00% to 0.52% in Jun 2023 quarter
- POSITIVE IMPACT
Price Rise
In the last 6 months, GLS stock has moved up by 62.6%
- POSITIVE IMPACT
Best in 1 Year
In the last 1 year, GLS has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 82.85% of holdings in Jun 2023 quarter
NEGATIVE IMPACTFII Holding Down
Foreign Institutions have decreased holdings from 3.29% to 3.27% in Jun 2023 quarter
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 13.86% to 13.30% in Jun 2023 quarter
Mutual Fund Holdings
| Funds | Holdings |
 Union Flexi Cap Fund Direct Growth Option | 0.98% |
| Union Small Cap Fund Direct Growth | 1.39% |
| Union Multicap Fund Direct Growth | 1.44% |
| Union Tax saver (ELSS) Fund Direct Plan Growth Option | 0.98% |
| Union Hybrid Equity Fund Direct Growth | 0.7% |
Glenmark Life Sciences Ltd Shareholding Pattern
| Investors | Holdings % | Prev. 2 periods | 3M change |
|---|---|---|---|
| Promoter Holdings | 82.85% | 0.00 | |
| Foreign Institutions | 3.27% | ||
| Mutual Funds | 0.52% | 257800.00 | |
| Retail Investors | 13.3% | ||
| Others | 0.06% | 8371.43 |
Technicals of Glenmark Life Sciences Ltd share
News & Events of Glenmark Life Sciences Ltd
Frequently Asked Questions
Glenmark Life Sciences Ltd (GLS) share price today is ₹617.95
- Today’s highest price of Glenmark Life Sciences Ltd is ₹626.9.
- Today’s lowest price of Glenmark Life Sciences Ltd is ₹617.05.
Today’s traded volume of Glenmark Life Sciences Ltd(GLS) is 1.82L.
Today’s market capitalisation of Glenmark Life Sciences Ltd(GLS) is ₹7619.35Cr.
| Glenmark Life Sciences Ltd(GLS | Price |
|---|---|
52 Week High | ₹675 |
52 Week Low | ₹370 |
Glenmark Life Sciences Ltd(GLS) share price is ₹617.95. It is down -8.45% from its 52 Week High price of ₹675
Glenmark Life Sciences Ltd(GLS) share price is ₹617.95. It is up 67.01% from its 52 Week Low price of ₹370
| Glenmark Life Sciences Ltd(GLS | Returns |
|---|---|
1 Day Returns | -3.9% |
1 Month Returns | 0.61% |
3 Month Returns | 9.26% |
1 Year Returns | 63.47% |